Danaher Corporation vs Franklin FTSE South Korea ETF — how do they compare? Danaher Corporation trades at $220.03 (market cap $152.87B), while Franklin FTSE South Korea ETF trades at $58.4 (market cap $1.83B). The key difference: Danaher Corporation is far larger — about 83.5× Franklin FTSE South Korea ETF's market cap, and Danaher Corporation pays a 0.74% dividend while Franklin FTSE South Korea ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Franklin FTSE South Korea ETF for 16 Days on average.
| DHR | FLKR | |
|---|---|---|
Market Cap | $152.87B | $1.83B |
Volume | 5,228,698 | 679,902 |
Sector | Health | Broad Market / Factor |
52-Week High | $242.05 | $72.25 |
52-Week Low | $161.91 | $27.09 |
Typical Hold Time | 69 Days | 16 Days |
Enterprise Value | $175.08B | — |
Dividend Yield | 0.74% | — |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →Franklin FTSE South Korea ETF seeks to track an index of South Korean equities. The fund provides exposure to companies listed in South Korea across multiple sectors.
Read more on FLKR →